| Vesna Sossi | Pacific Parkinson's Research Centre | Investigation of Treatment Related Compulsive Behaviours and Impulse Control Disorders in Parkinson's Disease |
| Vesna Sossi | Pacific Parkinson's Research Centre | The Study of Proton Therapy Dose Distribution |
| Vesna Sossi | Pacific Parkinson's Research Centre | Imaging Inflammation with PBR28 in healthy controls |
| A. Jon Stoessl | Pacific Parkinson's Research Centre | Imaging Tau Accumulation with PBB3 in Healthy Controls |
| A. Jon Stoessl | Pacific Parkinson's Research Centre | Tau and Neuroinflammation Imaging in Parkinson's Disease and Related Disorders |
| A. Jon Stoessl | Pacific Parkinson's Research Centre | The Evolution of Parkinson's Disease |
| A. Jon Stoessl | Pacific Parkinson's Research Centre | The Relationship Between Serotonergic Innervation and levadopa-Derived Dopamine Release in Parkinson's Disease: An In Vivo PET Study |
| A. Jon Stoessl | Pacific Parkinson's Research Centre | Exercise and Parkinson's Disease: The basis for motor and cognitive benefits |
| A. Jon Stoessl | Pacific Parkinson's Research Centre | Studies of Dopamine Pathways by PET |
| A. Jon Stoessl | Pacific Parkinson's Research Centre | Studies of Patients with a high Genetic Risk of Developing Parkinson's Disease; Studies on the Natural History of Sporadic and Inherited Parkinson's Disease |
| A. Jon Stoessl | Pacific Parkinson's Research Centre | Human PET Studies of the Monamine Vesicular Transporter and human PET studies of the D1 receptor/MVT (Sch/TBZ) |
| A. Jon Stoessl | Pacific Parkinson's Research Centre | C-11 Raclopride for human PET studies D2 Receptors (Raclopride) |
| A. Jon Stoessl | Pacific Parkinson's Research Centre | PET Studies of Cerebral Glucose Metabolism in Neurodegenerative and Related Disorders |
| A. Jon Stoessl | Pacific Parkinson's Research Centre | Treating Depression in Parkinson's Disease with Transcarnial Direct Current Stimulation |
| Robert Carruthers | Multiple Sclerosis Clinic, Neurology | Pilot Study of PET Imaging; Correlation with Advanced MRI and Optical Coherence Tomography (OCT) in MS |
| Lakshmi Yatham | Mood and Anxiety Disorders, Psychiatry | PET Studies of Dopamine Turnover and Release in Bipolar Disorder - Montreal Imaging Stress Task PET Study |
| Haakon Nygaard | Clinic for Alzheimer Disease and Related Disorders, Neurology | A Medium Chain Triglyceride INTervention for Alzheimer's Disease (A MINT for AD) Phase Study |
| Haakon Nygaard | Clinic for Alzheimer Disease and Related Disorders, Neurology | A Phase 2a Multi-Centre Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease |
| G. Y. Robin Hsiung | Clinic for Alzheimer Disease and Related Disorders, Neurology | Characterization of Dementia Due to Mixed Alzheimer and Subcortical Vascular Pathology |
| G. Y. Robin Hsiung | Clinic for Alzheimer Disease and Related Disorders, Neurology | A Phase II/III Randomized, Double-Blind, Placebo-Controlled Multi-Centre Study of 2 Potential Disease Modifying Therapies in Individual at Risk for and with Dominantlyy Inherited Alzheimer's Disease |
| G. Y. Robin Hsiung | Clinic for Alzheimer Disease and Related Disorders, Neurology | Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) |
| G. Y. Robin Hsiung | Clinic for Alzheimer Disease and Related Disorders, Neurology | Alzheimer's Disease Neuroimaging Initiative 2 (ADC-039) |
| G. Y. Robin Hsiung | Clinic for Alzheimer Disease and Related Disorders, Neurology | Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease Study (A4 Study) |
| G. Y. Robin Hsiung | Clinic for Alzheimer Disease and Related Disorders, Neurology | Medical Imaging Trial NEtwork of Canada (MINTEC) Protocol C6: Amyloid and glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients with Significant White Matter Disease |
| G. Y. Robin Hsiung | Clinic for Alzheimer Disease and Related Disorders, Neurology | A 24-month, multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study) |
| G. Y. Robin Hsiung | Clinic for Alzheimer Disease and Related Disorders, Neurology | Novel Retinal Biomarkerss for Alzheimer's disease(" Retinal Imaging for Dementia") |
| G. Y. Robin Hsiung | Clinic for Alzheimer Disease and Related Disorders, Neurology | A Phase 3 Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumb (BIIB037) in Subjects with Early Alzheimer's Disease |
| G. Y. Robin Hsiung | Clinic for Alzheimer Disease and Related Disorders, Neurology | A Phase III, Multicente, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab In Patients With Prodromal To Mild Alzheimer's Disease |
| Doris Doudet | Pacific Parkinson's Research Centre | Control Study for the Validation of C-11 yohimbine as a Selective Tracer for the Alpha 2 Adrenergic Receptors |
| Catharine A. Winstanley | Psychology | Dopamine release in Response to Gambling: a [11C]raclopride PET pilot study |
| Alexandre Henri-Bhargava | Clinical-Island Medical Program, Neurology | CREAD: A Phase III, Multicente, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab In Patients With Prodromal To Mild Alzheimer's Disease |
| Alexandre Henri-Bhargava | Clinical-Island Medical Program, Neurology | A 24-month, multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study) |
